Ser53
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser53  -  MED17 (mouse)

Site Information
RIDFSQGsGsEEEEA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4765330

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 , 3 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
liver cancer ( 1 )
Relevant cell line - cell type - tissue:
brain ( 3 ) , hepatocyte ( 1 ) , HepG2 (hepatic) ( 1 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 2 ) , spleen ( 3 ) , testis ( 3 )

Upstream Regulation
Putative in vivo kinases:
CK2A1 (human) ( 1 )
Kinases, in vitro:
CK2A1 (human) ( 1 )
Treatments:
insulin ( 1 ) , silmitasertib ( 1 )

Downstream Regulation
Effects of modification on MED17:
activity, induced ( 1 ) , intracellular localization ( 1 )
Effects of modification on biological processes:
transcription, induced ( 1 )

References 

1

Viscarra JA, Wang Y, Hong IH, Sul HS (2017) Transcriptional activation of lipogenesis by insulin requires phosphorylation of MED17 by CK2. Sci Signal 10
28223413   Curated Info

2

Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6
21659605   Curated Info

3

Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079   Curated Info